Dr. Steven Chatfield appointed as Non-Executive Chairman of Stablepharma, following an extensive career in vaccine R&D and Covid19 Pandemic.
Dr. Chatfield, who currently serves on Stablepharma’s Advisory Board, is taking on the role of Non-Executive Chairman of the company in November. He has been instrumental in advising and advancing the launch of SPVX02, a fridge-free vaccine designed for the prevention of Tetanus and Diphtheria (Td). His expertise will be invaluable as the company continues to scale and innovate in the vaccine and biologics sector.
CEO and Executive Director Özgür Tuncer expressed his enthusiasm about Dr. Chatfield transitioning into the role of Non-Executive Chairman, following the retirement of Dr. Bruce Roser, who co-founded Stablepharma in 2012. “Steve brings unrivalled knowledge and hands-on experience in the vaccine industry, having developed new healthcare interventions with a strong focus on vaccines and immunotherapy products to address infectious diseases.” Özgür added, “I would like to extend my thanks to Dr. Bruce Roser for his vision and his service as the founding Chairman of Stablepharma”.
Stablepharma’s technology platform, StablevaX™, enables the reformulation of biopharmaceuticals, vaccines, and diagnostic products into fridge-free forms that do not require refrigeration. This innovative technology significantly extends shelf life, reduces reliance on the global cold chain, lowers CO2 emissions, and minimizes vaccine wastage. By enhancing accessibility and sustainability, StablevaX™ is poised to make a substantial impact on global health initiatives.
“It is a privilege to take up the chair of Stablepharma, at a time when the company is progressing towards several key milestones in the development and commercialisation of their portfolio of fridge-free vaccine and pharmaceutical products”, said Dr Steven Chatfield. “What is really exciting about Stablepharma’s technology, is that it has the potential to abolish the cold chain for vaccine storage, which will address some of the major global challenges we face today with regard to distribution and deployment, and at the same time, reducing the impact on the environment by removing the cost and emissions of the global cold chain”. “This is an exciting and pivotal time for Stablepharma”.
With a long and varied career in the Life Sciences industry, Dr. Chatfield has a particular passion for helping organizations translate their research and guide technologies on the path to commercialisation. His expertise in this area has been especially valuable to Stablepharma’s commercial team as they work toward the launch of their first two fridge-free vaccines, SPVX02 and SPVX06. “From the beginning of my career I have always been focussed on developing vaccines that could be deployed more easily, particularly in LMIC countries”, added Steve.
As part of the team working for the Health Protection Agency, Dr. Chatfield was Director of the Centre for Emergency Preparedness and Response at Porton Down, responsible for protecting and responding to threats such as emerging diseases, pandemics and bioterrorist threats. He recently served on the Vaccines Task Force during the COVID 19 pandemic.
Özgür Tuncer added, “On behalf of the Board, I would like to welcome Dr. Steven Chatfield as our Non-Executive Chairman. We look forward to benefiting from his extensive experience and knowledge, and to collaborating with him in the months and years ahead.” This sentiment reflects the Board’s confidence in Dr. Chatfield’s leadership as they continue to advance Stablepharma’s mission.